FLT3 and acute myeloid leukemia: Currently, inhibitors targeting epigenetic modulations such as isocitrate dehydrogenase (IDH), fms-like kinase 3 (FLT3), lysine-specific histone demethylase 1A (LSD1), DOT1-like protein (DOT1L) and bromodomain and extraterminal (BET) proteins are under investigation to treat AML patients22,55.